Comerica Bank Decreases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Comerica Bank decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 272,635 shares of the biopharmaceutical company's stock after selling 14,039 shares during the period. Comerica Bank's holdings in Gilead Sciences were worth $25,183,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the business. Bridgewater Associates LP increased its holdings in Gilead Sciences by 122.7% in the 4th quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock worth $42,577,000 after purchasing an additional 253,994 shares in the last quarter. McAdam LLC boosted its position in Gilead Sciences by 16.7% during the 4th quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company's stock worth $2,344,000 after buying an additional 3,627 shares during the period. Capital Investment Advisors LLC grew its holdings in Gilead Sciences by 2.6% during the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company's stock worth $35,793,000 after acquiring an additional 9,791 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its position in Gilead Sciences by 3.9% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 142,167 shares of the biopharmaceutical company's stock valued at $13,132,000 after acquiring an additional 5,382 shares during the period. Finally, Global Financial Private Client LLC lifted its holdings in shares of Gilead Sciences by 1,222.0% during the fourth quarter. Global Financial Private Client LLC now owns 6,068 shares of the biopharmaceutical company's stock worth $561,000 after purchasing an additional 5,609 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Trading Down 0.9 %

Gilead Sciences stock traded down $0.89 during trading hours on Monday, reaching $102.79. The company had a trading volume of 5,459,401 shares, compared to its average volume of 7,519,245. The firm has a market cap of $127.99 billion, a price-to-earnings ratio of 277.81, a P/E/G ratio of 0.71 and a beta of 0.26. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The company has a 50-day moving average price of $108.69 and a 200 day moving average price of $98.99.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The firm's revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.32) EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be issued a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.07%. Gilead Sciences's dividend payout ratio is presently 66.53%.

Analyst Ratings Changes

A number of equities research analysts have commented on GILD shares. Morgan Stanley upped their price target on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. BMO Capital Markets boosted their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and increased their price objective for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. Piper Sandler upped their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. Finally, Bank of America boosted their price objective on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, Gilead Sciences presently has an average rating of "Moderate Buy" and an average price target of $110.55.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total transaction of $260,225.00. Following the transaction, the chief financial officer now owns 169,061 shares in the company, valued at approximately $17,597,559.49. This represents a 1.46 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 160,605 shares of company stock worth $16,718,136 over the last quarter. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.